Hikma PharmaceuticalsHKMPF 82 PEG Ratio is 2.12 as of Jul. 03, 2026, which is 6% below its 10-year median of 2.26. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.50 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 349 Drug Manufacturers companies, Hikma Pharmaceuticals ranks worse than 57.31% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Hikma Pharmaceuticals's PEG Ratio or its related term are showing as below:
HKMPF'
s PEG Ratio Range Over the Past 10 Years
Min: 0.44 Med: 2.26 Max: 12.47
Current: 2.12
During the past 13 years, Hikma Pharmaceuticals's highest PEG Ratio was 12.47. The lowest was 0.44. And the median was 2.26.
HKMPF's PEG Ratio is ranked worse than 57.31% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.69
vs HKMPF: 2.12
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Hikma Pharmaceuticals (OTCPK:HKMPF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Hikma Pharmaceuticals (HKMPF) has a PEG Ratio of 2.12 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Hikma Pharmaceuticals and its competitors. This is near median its historical median of 2.26. Over the past decade, Hikma Pharmaceuticals' PEG Ratio has ranged from 0.44 to 12.47. According to the industry distribution chart, Hikma Pharmaceuticals ranks #200 out of 349 companies in the Drug Manufacturers industry, placing it in the top 57.3%.
Is Hikma Pharmaceuticals' PEG Ratio too high?
Hikma Pharmaceuticals' current PEG Ratio of 2.12 is near median its 10-year median of 2.26. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 12.47. The Drug Manufacturers industry median PEG Ratio is 1.69. Hikma Pharmaceuticals' value of 2.12 is 25.4% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #200 out of 349 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #200 out of 349 companies for PEG Ratio. This places Hikma Pharmaceuticals in the lower half of its industry. The industry median PEG Ratio is 1.69. Hikma Pharmaceuticals' value of 2.12 is 25.4% above this benchmark. Historically, Hikma Pharmaceuticals' own PEG Ratio has ranged from 0.44 to 12.47 over the past decade. While the company's 10-year median is 2.26 vs. the industry median of 1.69, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.69, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current PEG Ratio of 2.12 is 25.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current PEG Ratio is 2.12, which is near median its own 10-year median of 2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.50, compared to a current price of $20.12 — trading 29.4% below its estimated fair value. The current PEG Ratio is 2.12, which is near median its 10-year median of 2.26 and 25.4% above the Drug Manufacturers industry median of 1.69. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current PEG Ratio is 2.12 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 29.4% below its estimated GF Value™ of $28.50.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
PEG Ratio: 2.12 (near median its 10-year median of 2.26)
GF Value™: $28.50 vs. price of $20.12 (29.4% below fair value)
Industry Position: 25.4% above the Drug Manufacturers median (#200 of 349)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
